BOSTON--(BUSINESS WIRE)--Ensoma, a genomic medicines company advancing the future of medicine through one-time, in vivo treatments capable of precisely and durably engineering the hematopoietic system ...
Ensoma Inc.’s lead program, EN-374, has been granted orphan drug and rare pediatric disease designations by the FDA for the treatment of X-linked chronic granulomatous disease. Ensoma anticipates ...
Chronic Granulomatous Disease (CGD) is a rare, inherited immunodeficiency caused by mutations in one or more components of the NADPH oxidase complex. This defect compromises the ability of phagocytes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback